Diaceutics Launches World’s First Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Diaceutics today launches world’s first digital platform solution to broken testing ecosystem DXRX – The Diagnostic Network®

Global pharma companies, labs and diagnostic companies are leveraging the platform with 38 laboratories and diagnostic companies onboarded and two pharma companies piloting the platform

DXRX provides access to pipeline of global diagnostic testing data on one secure platform and enables industry-wide collaboration to accelerate biomarker test adoption and time to peak therapy prescription from years to months

Early collaborations are now live on DXRX to address real-world cancer testing issues such as PD-L1 reimbursement in the US, and EQA Provision for NGS testing in EU and Asia

Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months. As a solution to today’s broken testing ecosystem, DXRX brings together stakeholders from across the industry to collaborate in a vibrant marketplace to solve real-world testing issues in a secure, standardized way for patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005588/en/

Sarah Colgan, Head of Global Marketing at Diaceutics (Photo: Business Wire)

DXRX integrates a pipeline of global diagnostic testing data into one secure platform providing access to transparent, real-time reporting on diagnostic utilization at a local level across multiple therapeutic areas.

Early collaborations between pharma, labs and diagnostic companies are live on the platform’s marketplace with 38 Laboratories and Diagnostic Companies onboarded from across EU, Asia and the US. These collaborations are designed to improve test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology.

The platform enables pharma clients to monitor and enhance test quality at local level to increase return on investment across multiple brands, and leverage a broad network of local partnership opportunities to implement best-in-class testing for their precision medicine portfolios. DXRX also enables clients to outsource the end-to-end diagnostic development and commercialization process from biomarker discovery to in-market test availability in order to reduce time to market for new therapies.

Furthermore, DXRX also provides users access to a global expert advisory panel of key opinion leaders from the areas of oncology, including lung cancer research and colorectal research; pathology, including tissue pathology and uropathology; molecular diagnostics; digital image analysis; telemedicine and informatics; external quality assessment (EQA); and FDA-expertise.

The end-to-end service offering provided by DXRX is enabled by a growing network of industry leading service providers in 51 countries. They cover precision medicine diagnostics to deliver implementation services such as test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Recent partnerships include Histocyte Laboratories, Targos Molecular Pathology, EMQN CIC, CPQA-ACP, NordiQC and UKNEQAS ICC & ISH.

An

Read more